Inactive Instrument

All News Stellar Biotechnologies Inc Nasdaq

Equities

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS	06-24	CI
Edesa Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-10	CI
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference	04-12	AQ
Edesa Biotech to Participate in Barclays Global Healthcare Conference	03-08	AQ
Top Premarket Gainers	03-05	MT
Edesa Biotech, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-09	CI
Edesa Biotech, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	12-15	CI
Top Premarket Decliners	12-13	MT
HC Wainwright Adjusts Price Target on Edesa Biotech to $21 From $70, Keeps Buy Rating	11-29	MT
Top Premarket Gainers	11-22	MT
Edesa Biotech, Inc. Reports Final Phase 2b Results for Dermatitis Study	11-20	CI
Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug	26/10/23	AQ
Edesa Biotech, Inc. Approves Updated Phase 3 Trial Design for Edesa Biotech?S ARDS Drug	25/10/23	CI
Top Premarket Decliners	13/10/23	MT
Sector Update: Health Care Stocks Decline in Late Afternoon	12/10/23	MT
Sector Update: Health Care	12/10/23	MT
Top Midday Gainers	12/10/23	MT
Edesa Biotech, Inc. to Receive Up to CAD 23 Million in Funding from Federal Government	12/10/23	CI
Edesa Biotech to Implement 1-for-7 Reverse Share Split; Stock Declines	10/10/23	MT
Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate	29/09/23	AQ

No results for this search